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Abstract
Background: Much attention has been devoted to ethical issues related to randomized controlled
trials for HIV treatment and prevention. However, there has been less discussion of ethical issues
surrounding families involved in observational studies of HIV transmission. This paper describes the
process of ethical deliberation about how best to obtain informed consent from sex partners of
injection drug users (IDUs) tested for HIV, within a recent HIV study in Eastern Europe. The study
aimed to assess the amount of HIV serodiscordance among IDUs and their sexual partners, identify
barriers to harm reduction, and explore ways to optimize intervention programs. Including IDUs,
either HIV-positive or at high risk for HIV, and their sexual partners would help to gain a more
complete understanding of barriers to and opportunities for intervention.
Discussion: This paper focuses on the ethical dilemma regarding informed recruitment: whether
researchers should disclose to sexual partners of IDUs that they were recruited because their
partner injects drugs (i.e., their heightened risk for HIV). Disclosing risks to partners upholds the
ethical value of respect for persons through informed consent. However, disclosure compromises
the IDU's confidentiality, and potentially, the scientific validity of the research. Following a brief
literature review, we summarize the researchers' systematic evaluation of this issue from ethical,
scientific, and logistical perspectives. While the cultural context may be somewhat unique to
Eastern Europe and Central Asia, the issues raised and solutions proposed here inform
epidemiological research designs and their underlying ethical tensions.
Summary: We present ethical arguments in favor of disclosure, discuss how cultural context
shapes the ethical issues, and recommend refinement of guidance for couples research of
communicable diseases to assist investigators encountering these ethical issues in the future.
Background
An estimated 33 million people are infected with HIV
worldwide, including about 2.5 million newly infected in
the past year. [1] Efforts to curb HIV transmission address
a host of social, cultural, and clinical issues through
important and diverse research studies to improve preven-
tion and intervention methods. While much attention has
been paid to the research ethics surrounding clinical trials
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of HIV treatment and prevention, [2-20] less discussion
has focused on observational studies of HIV transmission
involving sex partners. Couples research is crucial to inter-
vention development and raises unique ethical dilemmas
that are not specifically addressed by regulations, laws,
and ethical standards [2-4,21-23].
In couples research, the primary ethical tension entails
balancing the risks and benefits to the participating indi-
viduals, to the couple, and to society. Complicating the
issue, the investigators' ability to conduct scientifically
valid research may be inversely related to their ability to
fully protect the well-being of individual participants. For
example, in studies of sexual transmission of HIV among
injection drug users (IDU) and their partners, we typically
recruit IDUs and ask that they recruit their sexual partners.
Informing sexual partners that they are eligible for the
study because the partner is an IDU – a group with high
HIV prevalence – may immediately prompt them to
change their risk behaviors or leave the relationship
thereby biasing estimates of transmission rates. The dis-
closure of risks to sexual partners can also be justified as a
means of minimizing harms to others. Yet not informing
the partners may result in investigators watching the nat-
ural course of disease transmission in an uncontrolled
environment. Couples research thus raises important
questions: What are researchers' obligations to disclose
information about HIV risk when HIV risk is a central
component of study selection and eligibility? How much
information should be provided to potential recruits
about their risk as part of the informed consent process?
How do researchers balance the rights of each individual
within a couple, and study validity, in the informed con-
sent process?
This paper focuses on ethical dilemmas that arise when
IDUs are recruited into behavioral research on HIV that
will involve their sexual partners. Should researchers dis-
close to these partners that they were recruited because
their partner injects drugs (i.e., their heightened risk for
HIV)? Disclosing would uphold the ethical value of
respect for persons and serves to minimize harm to them.
However, in research involving couples, disclosure com-
promises the IDU's confidentiality. Investigators may
have conflicting obligations to members of the couple,
such as in this study: there is a conflict between protecting
the interests in confidentiality of the IDUs recruited for
the study and protecting the interests of their sexual part-
ners – some of whom may not know their partner is an
IDU – in being able to make informed choices. Disclosure
also potentially weakens the scientific validity of the
research if it causes some IDUs not to enroll because they
do not want this disclosure to be made. Following a brief
literature review, we summarize the researchers' system-
atic evaluation of this issue from ethical, scientific, and
logistical perspectives. While the cultural context may be
somewhat unique to Eastern Europe and Central Asia, the
issues raised and solutions proposed here inform epide-
miological research designs and their underlying ethical
tensions.
The tension between confidentiality and informed recruit-
ment in HIV transmission research first received consider-
able attention with the publication of a Ugandan cohort
study conducted between 1994 and 1998. [24-28]
Researchers identified 415 HIV-discordant couples from a
large randomized trial designed to study the impact of
bacterial sexually transmitted diseases on HIV transmis-
sion. [24] The couples were then followed to identify fac-
tors associated with HIV transmission. Substantial harm
reduction education, free condoms, and voluntary, confi-
dential HIV testing and counseling were offered to all par-
ticipants. However, researchers were legally obligated not
to inform participants who were HIV-negative about their
partners' HIV-positive status. Debate ensued about the
choice of confidentiality versus disclosure of partner HIV
status. [25-28] A decade later the debate continues with
no clear resolution.
The issue is further complicated by the legal issues that
surround HIV. In much of the world, including some US
states [29] and European countries, [30] disclosure by a
physician of an individual's HIV status without the
patient's consent is illegal. In other locations, physicians
have a duty to warn partners through mandated notifica-
tion programs.[31] Further, professional ethics codes may
differ from local laws, complicating these issues.[32]
Lastly, laws pertaining to medical care and observational
research conducted outside medical settings may differ.
Informed consent of research study participants begins
with the recruitment process. Typically, recruiting couples
starts with recruitment of the "index-participant" – indi-
viduals either infected with HIV or at very high risk for
HIV (e.g., IDU). The sexual partner is commonly recruited
with the assistance of the index-participant. The extent of
information disclosed to sex partners as to why they are
being sought for study inclusion remains controversial.
Some studies involve specific information about eligibil-
ity related to substantial HIV risk while others do not.
Major initiatives, such as the HIV Prevention Trial Net-
work (HPTN), have developed formal guidelines that
address fundamental research ethics issues, but these do
not prescribe a specific approach for "informed selec-
tion."[2] Providing accurate HIV risk information during
the informed consent process to all participants is consist-
ent with the HPTN guidelines (Sugarman J, personal com-
munication, 2008). The UN AIDS guidance for HIV
prevention trials also highlights that individuals be told
the specific reason for study eligibility. [4]BMC Medical Ethics 2009, 10:14 http://www.biomedcentral.com/1472-6939/10/14
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HIV in Estonia
In Estonia, the primary reservoir for HIV is the IDU com-
munity. By the turn of the century, this small Baltic state
had the highest HIV incidence in Europe.[33,34] Similar
to nearby cities in Russia, the IDU community was the
epicenter of the epidemic, and HIV spread quickly during
the post-independence transition period of the late
1990s.[34,35] About half of all IDUs in Estonia are
infected with HIV and over 90% are infected with hepati-
tis C virus (HCV). [36-38] The transmission of HIV
between IDUs is well understood and some intervention
programs are available, including free voluntary coun-
seling and testing, needle exchange programs and drug
treatment. [39-50] However, improved HIV prevention
and intervention programs are critically needed to curb
the spread of HIV among IDUs in general, and between
IDUs and their sexual partners. [39,40,45,51-54]
The primary mode of HIV transmission from the IDU
community to the general population is thought to be
through sexual contact.[45] However, insufficient
research has focused on improving interventions to inter-
rupt sexual transmission between IDUs and their partners.
Because the IDU community is a substantial reservoir for
HIV in Eastern Europe and Central Asia, understanding
and stopping transmission from this group is essential to
slow the spread of the epidemic. These studies must be
conducted against the backdrop of a changing social struc-
ture in the region, largely related to major changes in the
political and economic environment following independ-
ence.
Discussion
The Estonian Study
The study discussed here, a joint project of Estonian and
US researchers, took place in 2007 following Institutional
Review Board approval for the study granted by both US
and Estonian institutions. The study objectives were three-
fold: 1) assess the amount of HIV serodiscordance among
IDUs and their sexual partners, 2) identify barriers to
harm reduction, and 3) explore ways to optimize inter-
vention programs. Thus, we wanted to include IDUs,
either HIV-positive or at high risk for HIV, and their sexual
partners to gain a more complete understanding of the
barriers to and opportunities for intervention.
Injection drug users were recruited into research through
harm reduction programs, at known locations of drug use,
and by using respondent-driven sampling.[55,56] Once
an IDU was recruited, he/she was asked to invite both a
sexual partner(s) who does not use injection drugs and
other IDUs to participate in the study. Index-participants
were given two sets of coded cards to hand out (one set for
sexual partners and the other for IDUs as part of respond-
ent-driven sampling). Each individual was provided a
written informed consent form after the researcher orally
disclosed the purpose of the study, procedures, risks and
benefits of participation, participants' rights, and pro-
vided an opportunity to read the form (containing the
same information on the study) and ask questions. Each
participant was interviewed separately and blood was
obtained for HIV and HCV testing. The survey tool col-
lected detailed information about drug use, sexual behav-
iors, HIV testing, knowledge about HIV transmission, and
attitudes about HIV. Anonymous codes linked records.
(Anonymity was important because IDU is a crime in
Estonia [57,58] and the equivalent of a US Certificate of
Confidentiality [59,60] does not exist to protect partici-
pant data.) All participants received counseling as part of
the HIV testing and the counseling program provided in
Estonia. All participants were asked to return for test
results. Every aspect of the study was reviewed multiple
times by the investigators to ensure IDUs received ade-
quate protection.
Informed Consent Process
During the informed consent process, research staff took
great care to be transparent regarding all aspects of the
research study. All participants were told we were specifi-
cally studying HIV, including it's potential to be sexually
transmitted, and provided counseling around HIV testing.
We explained to IDUs the reason for recruitment and all
relevant study procedures. But it was less clear what to dis-
close to the recruited sex partners. To fully inform sexual
partners of the study's purpose and specific reason for
their study eligibility might require a disclosure of the
index-participants' drug use and heightened risk of HIV.
Thus, the crux of the ethical dilemma was the informed
consent process for the sexual partners, and specifically the
explanations about partner selection and the study pur-
pose. Our team generated multiple conceptual options for
informed consent statements, with the varying levels of
detail in italics for comparison:
1. "You were selected to participate in this study on
relationships and risk behaviors because your partner vol-
unteered for the study and was asked to invite his/her
sex partner."
2. "You were selected to participate in this study of
injection drug users and their sex partners because your
partner volunteered for the study and was asked to
invite his/her sex partner."
3. "You were selected to participate in this study of
injection drug users and their sex partners because your
partner volunteered for this study and was asked to
invite his/her sex partner. About half of injection drug
users are infected with HIV and we are particularly inter-BMC Medical Ethics 2009, 10:14 http://www.biomedcentral.com/1472-6939/10/14
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ested in understanding risk behaviors of injection drug users
who are infected with HIV and their partners. In particu-
lar, we want to learn what behaviors result in the highest
risk of HIV transmission and better ways to reduce risk of
transmission."
The first statement provides no information to the part-
ners recruited for the study about their risk of infection
now or in the near future. The second statement differs
from the first by specifying that the partner is an IDU. This
information is especially revealing because it is common
knowledge among residents of Estonia that many IDUs
are HIV positive. The third statement clearly states part-
ners' potential risk of HIV if they are not actively prevent-
ing transmission (e.g., using condoms).
The research team was unable to use the third statement,
due to concerns of the local ethics committee about such
specific, yet ambiguous communication that could further
stigmatize IDUs. While it may appear arbitrary that one
stigma (i.e., IDU status) can be shared while another (i.e.,
HIV status) can not, it is not uncommon that inconsisten-
cies in sensitivity about exposures exist in many countries.
The research team debated the first two options at length.
The decision would have health, scientific, and ethical
consequences. In the following we describe the process we
underwent and factors that informed our decision.
The Process of Ethical Deliberation
Investigators originally planned to use the first statement,
that is, to not disclose the study's primary focus on IDUs
and HIV transmission risk to their sexual partners. Driven
by our prior experience with vulnerable populations, we
designed the study to fully protect IDUs while maximiz-
ing their comfort with participating in the research
project. However, further reflection on the public health
and ethical implications of this approach to disclosure led
the research team to reconsider. We sought input from
multiple sources for over a year prior to study implemen-
tation, including informal conversations with IDUs,
NGOs (e.g., needle exchange programs), researchers, eth-
icists, friends and family members of IDUs, and others
As the discussion unfolded, substantial concern focused
on the asymmetrical knowledge between investigators
and study participants. The researchers would know more
about the risk of continued unprotected intercourse with
the index-participant (e.g., discordant HIV status, rare or
no use of condoms) than the partner. Proponents of part-
ner notification advocate a defined legal limit on confi-
dentiality of the physician-patient relationship, the value
of providing life-saving treatment for infected partners,
and overall benefit to the public's health. Challengers to
partner notification question whether mandatory partner
notification laws for HIV will have an overall negative
impact on both medical care and public health due to the
loss of patients' ability to trust their physicians with sensi-
tive information. [61-64] Investigators must consider
many factors when developing a research study that figure
into designing the process of informed consent. The key
factors that arose in our research deliberations included
protection of vulnerable populations, confidentiality
waivers, validity of scientific results, differential risk for
partners based on informed consent, and research logis-
tics, all of which are discussed below.
Protection of Vulnerable Populations
In Estonia, research ethics committees consider IDUs
among the vulnerable potential study participants.
Known IDUs are marginalized for several reasons, includ-
ing: a) their (illegal) behavior, b) most are members of an
ethnic minority (about 80% are Russian-speaking), c)
many have served time in jail or prison, d) many are poor,
and e) about half are known to be HIV positive [34]
Sex partners of IDUs, who are not themselves IDUs, typi-
cally share only two of these vulnerabilities: Russian-
speaking minority and low socioeconomic status.
Another important factor to consider related to vulnera-
bility is that divorce in Estonia is not uncommon. [65] As
partners learn of the index-participant's HIV/IDU status,
they may consider the option of divorce. Divorce is a
socially acceptable option, and viable since sufficient
housing exists in Estonia. By contrast, leaving a sexual
partner is not a viable cultural or economic option in
many other countries.
Confidentiality Waiver
For the IDU participants, requiring disclosure about drug
use may result in feelings of vulnerability or frustration if
they want to participate but do not want disclosure.
Ensuring the confidentiality of study participants is a par-
amount human subjects projection. However, other
equally pressing human subjects protections – informing
partners of why they are being recruited into the study,
must be balanced against protecting the confidentiality of
the IDU. Accordingly, research participants commonly
provide limited waivers of confidentiality for many stud-
ies. These waivers may be for protected information to be
provided to researchers (e.g., medical records) or dis-
closed among research participants (e.g., research on cou-
ples or family counseling). In these situations,
participants typically provide waivers of confidentiality
that are limited to requirements for good scientific
research. Indeed, in our study the index-participant will-
ingly disclosed their sexual relationship with the referred
partner(s).
Is there an ethical difference between requiring informa-
tion disclosure about a person's drug use or HIV infection
compared to disclosing information about a person's sex-
ual relationship in order to participate in the study? Dis-BMC Medical Ethics 2009, 10:14 http://www.biomedcentral.com/1472-6939/10/14
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closure of IDU in Estonia to a partner could present
significant harms to the IDU. In Estonia, not only is IDU
illegal, but it is also illegal for a person who knows he/she
is HIV-positive to transmit HIV to a person who was not
aware of this risk, and criminal convictions have occurred.
[66]
Conversely, waiving limited confidentiality is commonly
required in research. If the requirements for research par-
ticipation are unacceptable, then individuals can choose
not to participate. In Estonia, the same HIV testing is free
and available as is the counseling provided to study par-
ticipants, which is comparable to that provided in the
wider community. Thus, there is no overly compelling
benefit for individuals to participate. The study's modest
compensation was attractive to community members but
not excessive such that a typical low-income IDU would
unduly agree to unacceptable conditions. (This assess-
ment was validated by the fact that some IDUs did not
participate and others did not refer partners.)
Validity of Research Findings
For a research study to be ethical it must be scientifically
valid. No risk is warranted if the study cannot be inform-
ative. From an epidemiologic perspective, the greatest risk
to generalizability regarding informed recruitment is
selection bias. If index-participants know that their sex
partner(s) will be told about their drug use, then only
partners who already know about this risk behavior will
likely be referred for participation. Limitations on study
participation driven by the consent process would, in
turn, limit the effectiveness of resultant interventions to
those with characteristics similar to the group studied.
While our study was cross-sectional, the same issue
applies to longitudinal studies designed to estimate HIV
transmission rates more broadly.
Based on interviews with IDUs, we hypothesize that drug
users who do not want their partners to know about their
drug use are unlikely to recruit them for a study on HIV
risk and transmission. It is not only the researchers who
the IDU must trust, but also the other individuals the part-
ner may encounter at the research location. Thus, the pri-
mary disadvantage of informed recruitment – selection
bias – may likely be introduced by study participants, and
that additional selection bias introduced by an in-depth
informed consent is minimal. While empirical research is
needed to formally test this hypothesis, it is supported by
other researchers' experience working with IDUs (D. Des
Jarlais, personal communication, 2008).
Risk
Arguments against and in favor of disclosure of the index
participant's IDU status can be made depending on differ-
ent interpretations of risk of HIV transmission to the pub-
lic's health. A key argument against disclosure is that
research participation does not increase the risk of HIV
transmission/infection by participants. Even if the sex
partners were not informed of the IDU status of the index
participants during the recruitment process, all partici-
pants received state-of-the art education about behavioral
risk factors and harm reduction techniques, which should
minimize their risk of transmission. Another argument is
that providing additional risk information does not nec-
essarily enhance the study participant's protection. Empir-
ical research shows that these educational and behavioral
risk reduction interventions minimally affect sexual
behavior. [51-54] That is, many partners continue to
undertake risky sexual relations with IDUs after being
informed. Accordingly, if the study provides limited risk
reduction benefit, why introduce the potential for selec-
tion bias that would jeopardize the results? Such empiri-
cal evidence may lead some to conclude that disclosure is
not necessary. For these and other reasons, nondisclosure
of the index participant's IDU status is still commonly
practiced in the US and abroad.
Nevertheless, there are substantial arguments in favor of
disclosure. First, informing partners, who are study partic-
ipants, enables them to become aware of the urgency with
which to undertake precautions. It is imperative to ensure
that potential study participants make informed choices,
even if how they choose to act thereafter may not be
healthful. Thus, doing so minimizes harms to study par-
ticipants. Another justification for disclosure may be
drawn from interviews with the IDUs in Estonia. Many
partners leave the relationship upon learning about drug
use. Because HIV is substantially more prevalent in the
IDU community, leaving a relationship with an IDU does
reduce a partner's risk of HIV infection. Thus, from the
partners' perspective, this is an effective method of risk
reduction that they can take and many are willing to take.
Moreover, nondisclosure may pose the potential for emo-
tional harm to partners and the broader community if it
became known that researchers knew some HIV-negative
participants were having unprotected sex with HIV-posi-
tive individuals. Partners may feel betrayed and the com-
munity may feel manipulated. Such feelings could easily
transform into distrust and reluctance to participate in
research in the future, as has occurred among African
Americans in the US. [67,68]
Logistics
Paper forms were used for most data collection, causing a
delay in data entry. While the index-participant's IDU sta-
tus was known, most partners were enrolled before infor-
mation about HIV status was available. Nonetheless,
studies of HIV transmission that include diverse risk
groups and follow the transmission risk to multiple sexBMC Medical Ethics 2009, 10:14 http://www.biomedcentral.com/1472-6939/10/14
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partners may benefit from rapid tests and real time data
processing to provide appropriate information about dis-
ease risk to recruited individuals. Without these technolo-
gies, general statements related to risk of HIV can be made
to all participants.
Resolution
For our study, we could not add IDU information to the
partner's informed consent form because of the legal con-
cerns about revealing HIV status. Thus, our pragmatic
compromise was to tell all index participants to only
recruit sex partners who knew about their drug use.
Summary
During the design phase of this study, we identified ethi-
cal tensions unique to the process of studying couples.
From an epidemiological perspective, when the couple is
of central interest then it is the unit of study and analysis.
However, from a research ethics perspective, the individu-
als, the couple, and the greater community all are impor-
tant to consider and warrant human subjects protections.
At times what is best for one person in a couple may not
be best for the other. For couples research pertaining to
HIV sexual transmission, we posit that failing to fully
inform partners about the rationale for inclusion in the
study is ethically disconcerting. Intentionally limiting dis-
closure to sexual partners remains ethically problematic
given the potential for continued risk that exists among
HIV-discordant couples with unsafe sex behaviors. While
institutional review boards have developed sensitivity to
cultural appropriateness for research in developing coun-
tries, refinement of guidance for couples research of com-
municable diseases is needed to address ethical issues
such as those raised herein.
We suggest that further guidance for both cross-sectional
and longitudinal studies of HIV transmission is needed
regarding informed recruitment. While in our example
recruitment was anonymous and limited to IDUs and
their sexual partners, in longitudinal HIV transmission
studies researchers recruit diverse risk groups (e.g., IDU,
commercial sex workers, MSM) and follow transmission
for multiple waves. Thus, specific HIV risk (e.g., HIV status
of sexual partners) often will not be known at the time of
study interviews. We suggest that research participants can
be accurately told that they were recruited for the study
because they are connected to a group at higher risk for
HIV then the general population. The detailed explana-
tion of this risk may vary by wave of recruitment and by
region. Additionally, in longitudinal studies, we suggest
research participants be reminded that they were recruited
for the study due to their high risk for becoming infected
with HIV and harm reduction counseling be provided
with each follow-up blood test.
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